<img align="left" hspace="5" src="https://pharmashots.com/public/images/20240212125438_original_49.webp"/>CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)




CSL has reported top-line results from the P-III (AEGIS-II) study assessing the safety and efficacy of CSL112 vs PBO to reduce recurrent cardiovascular events at a duration of 90 days in patients (n=18,200) following AMI
The results revealed that the trial was unable to meet the 1EP of major adverse cardiovascular events (MACE) reduction at 90 days due to which no near-term regulatory filing is anticipated. Further analysis is in progress
CSL112 [Apolipoprotein A-I (Human)], a cholesterol efflux enhancer, is developed with a novel formulation of human plasma-derived Apolipoprotein A-I (apoA-I) that is the primary functional component of high-density lipoproteins (HDL)

Ref: CSL | Image: CSL

Related News:- CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com



Source link

Leave A Reply

Your email address will not be published.